MA52424B1 - Compositions pharmaceutiques comprenant du (2s)--((1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl)-1,4-oxazepane-2-carboxamide - Google Patents
Compositions pharmaceutiques comprenant du (2s)--((1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl)-1,4-oxazepane-2-carboxamideInfo
- Publication number
- MA52424B1 MA52424B1 MA52424A MA52424A MA52424B1 MA 52424 B1 MA52424 B1 MA 52424B1 MA 52424 A MA52424 A MA 52424A MA 52424 A MA52424 A MA 52424A MA 52424 B1 MA52424 B1 MA 52424B1
- Authority
- MA
- Morocco
- Prior art keywords
- pharmaceutical compositions
- oxazepane
- benzoxazol
- carboxamide
- dihydro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des compositions pharmaceutiques appropriées pour une administration orale, et plus particulièrement des compositions pharmaceutiques, notamment des compositions de comprimés pharmaceutiques, contenant du (2S)-N- { (1S)-1-cyano-2-[4- (3-méthyl-2-oxo-2,3-dihydro -1,3-benzoxazol-5-yl) phényl]éthyl}-1,4-oxazépane-2-carboxamide (composé A) ou un sel pharmaceutiquement acceptable de celui-ci.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862636944P | 2018-03-01 | 2018-03-01 | |
| PCT/EP2019/055138 WO2019166626A1 (fr) | 2018-03-01 | 2019-03-01 | Compositions pharmaceutiques comprenant du (2s)-n-{(1s)-1-cyano-2-[4-(3-méthyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phényl]éthyl}-1,4-oxazépane-2-carboxamide |
| EP19716296.9A EP3758708B1 (fr) | 2018-03-01 | 2019-03-01 | Compositions pharmaceutiques comprenant du (2s)-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA52424A MA52424A (fr) | 2021-01-06 |
| MA52424B1 true MA52424B1 (fr) | 2025-04-30 |
Family
ID=66102025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA52424A MA52424B1 (fr) | 2018-03-01 | 2019-03-01 | Compositions pharmaceutiques comprenant du (2s)--((1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl)-1,4-oxazepane-2-carboxamide |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US12059424B2 (fr) |
| EP (2) | EP3758708B1 (fr) |
| JP (2) | JP7336450B2 (fr) |
| KR (2) | KR102738945B1 (fr) |
| CN (3) | CN112055593B (fr) |
| AU (3) | AU2019228717C1 (fr) |
| CA (1) | CA3091707A1 (fr) |
| DK (1) | DK3758708T3 (fr) |
| ES (1) | ES3011730T3 (fr) |
| FI (1) | FI3758708T3 (fr) |
| HR (1) | HRP20250115T1 (fr) |
| HU (1) | HUE070049T2 (fr) |
| LT (1) | LT3758708T (fr) |
| MA (1) | MA52424B1 (fr) |
| MD (1) | MD3758708T2 (fr) |
| PL (1) | PL3758708T3 (fr) |
| PT (1) | PT3758708T (fr) |
| RS (1) | RS66494B1 (fr) |
| SI (1) | SI3758708T1 (fr) |
| SM (1) | SMT202500062T1 (fr) |
| WO (1) | WO2019166626A1 (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2699580T3 (fr) | 2014-01-24 | 2018-02-24 | ||
| WO2018022978A1 (fr) * | 2016-07-29 | 2018-02-01 | Insmed Incorporated | Certains (2s)-n-[(1s)-1-cyano-2-phényléthyl]-1,4-oxazépane-2-carboxamides pour le traitement de la bronchectasie. |
| PT3758708T (pt) | 2018-03-01 | 2025-02-13 | Astrazeneca Ab | Composições farmacêuticas compreendendo (2s)-{(1,s)-1-ciano-2-[4-(3-metil-2-oxo-2,3-di-hidro-1,3-benzoxazol-5-il)fenil]etil}-1,4-oxazepano-2-carboxamida |
| CA3106269A1 (fr) | 2018-07-17 | 2020-01-23 | Insmed Incorporated | Certains (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides pour le traitement d'une nephropathie lupique |
| AU2021314104A1 (en) | 2020-07-20 | 2023-01-19 | Insmed, Inc. | Methods for extracting neutrophil serine proteases and treating dipeptidyl peptidase 1-mediated conditions |
| WO2022166721A1 (fr) * | 2021-02-05 | 2022-08-11 | 南京明德新药研发有限公司 | Dérivés cycliques fusionnés contenant du 1,4-oxazépane |
| US20240226112A1 (en) * | 2021-04-29 | 2024-07-11 | Insmed Incorporated | Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis |
| CN115925696A (zh) * | 2021-10-29 | 2023-04-07 | 瑞石生物医药有限公司 | 一种1-氰基-2-苯基乙基甲酰胺衍生物及其用途 |
| CN118159525A (zh) * | 2021-10-29 | 2024-06-07 | 英斯梅德股份有限公司 | 用于治疗慢性鼻窦炎的特定n-(1-氰基-2-苯乙基)-1,4-氧杂氮杂环庚烷-2-甲酰胺 |
| US20250101011A1 (en) * | 2022-01-11 | 2025-03-27 | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd | Peptidyl nitrile compound and use thereof |
| JP2026503035A (ja) | 2023-01-06 | 2026-01-27 | インスメッド インコーポレイテッド | 新規な可逆性dpp1阻害剤及びその用途 |
| JP2026510407A (ja) * | 2023-03-23 | 2026-04-02 | ハイスコ ファーマスーティカル プライベート リミテッド | ジペプチジルペプチダーゼ小分子阻害剤を含む医薬組成物 |
| WO2025162472A1 (fr) | 2024-01-31 | 2025-08-07 | Insmed Incorporated | Inhibiteurs linéaires de la dipeptidylpeptidase 1 et leurs utilisations |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6297239B1 (en) | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| US6462076B2 (en) | 2000-06-14 | 2002-10-08 | Hoffmann-La Roche Inc. | Beta-amino acid nitrile derivatives as cathepsin K inhibitors |
| DE60131423T2 (de) | 2000-09-08 | 2009-03-19 | Prozymex A/S | Ratten-spezifische cathepsin, dipeptidyl peptidase i (dppi): kristallstruktur, hemmstoffe und deren anwendungen |
| US20110236367A1 (en) | 2000-09-08 | 2011-09-29 | Telenav, Inc. | Rat cathespin dipeptidyl peptidase i (dppi): crystal structure and its uses |
| EP1217000A1 (fr) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibiteurs du factor Xa et factor VIIa |
| PL370766A1 (en) | 2001-12-04 | 2005-05-30 | F.Hoffmann-La Roche Ag | Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors |
| US20040253311A1 (en) | 2002-12-18 | 2004-12-16 | Roger Berlin | Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines |
| WO2004076434A1 (fr) | 2003-02-28 | 2004-09-10 | Aic | Inhibiteurs de dipeptidyl peptidases |
| WO2004087153A2 (fr) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Utilisation de petites molecules de composes pour une immunopotentialisation |
| WO2004106289A1 (fr) | 2003-05-30 | 2004-12-09 | Prozymex A/S | Inhibiteurs de protease |
| WO2004110988A1 (fr) | 2003-06-18 | 2004-12-23 | Prozymex A/S | Inhibiteurs de la protease |
| KR101637908B1 (ko) | 2004-04-07 | 2016-07-11 | 리나트 뉴로사이언스 코프. | 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법 |
| EP1745292A2 (fr) | 2004-04-28 | 2007-01-24 | Bayer HealthCare AG | Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 1 (dpp1) |
| US7618981B2 (en) | 2004-05-06 | 2009-11-17 | Cytokinetics, Inc. | Imidazopyridinyl-benzamide anti-cancer agents |
| BRPI0508063A (pt) | 2004-06-29 | 2007-07-17 | Nycomed Danmark Aps | processo para a manufatura de uma composição farmacêutica, nsaid, e, composição farmacêutica |
| JP5704785B2 (ja) | 2004-07-19 | 2015-04-22 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 免疫抑制のためのflt3阻害剤 |
| CN103169729A (zh) | 2005-02-18 | 2013-06-26 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
| EP1896461A2 (fr) | 2005-06-30 | 2008-03-12 | Amgen Inc. | Inhibiteurs de bis-aryl kinase et leur utilisation pour le traitement de l'inflammation, de l'angiogenese et du cancer |
| AU2008223348A1 (en) | 2007-03-07 | 2008-09-12 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors containing a heterocyclic moiety |
| WO2009026701A1 (fr) | 2007-08-29 | 2009-03-05 | Methylgene Inc. | Inhibiteurs de sirtuine |
| KR20100060004A (ko) | 2007-09-25 | 2010-06-04 | 노파르티스 아게 | 에어로졸화된 반코마이신과 같은 의약에 의한 폐 질병의 치료 |
| US7902181B2 (en) | 2007-12-12 | 2011-03-08 | Astrazeneca Ab | Compounds 010 |
| US9315449B2 (en) | 2008-05-15 | 2016-04-19 | Duke University | Substituted pyrazoles as heat shock transcription factor activators |
| PE20100252A1 (es) | 2008-06-06 | 2010-04-12 | Boehringer Ingelheim Int | Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina |
| RU2016116516A (ru) | 2008-12-08 | 2018-12-07 | Мандифарма Интернэшнл Корпорейшн Лимитед | Композиции ингибиторов тирозинкиназных рецепторов белков |
| PT2413913T (pt) | 2009-04-01 | 2022-06-09 | Bial Portela & Ca Sa | Formulações farmacêuticas que compreendem derivados de nitrocatecol e métodos para os preparar |
| EA201190235A1 (ru) | 2009-05-07 | 2012-05-30 | Астразенека Аб | Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750 |
| WO2010142985A1 (fr) | 2009-06-10 | 2010-12-16 | Astrazeneca Ab | Composés 761 n-[1-cyano-2-(phényle)éthyle]pipéridine-2-ylcarboxamide substitués |
| ES2900353T3 (es) * | 2010-04-07 | 2022-03-16 | Vertex Pharma | Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas |
| WO2011154677A1 (fr) | 2010-06-09 | 2011-12-15 | Astrazeneca Ab | Composés n-[1-cyano-2-(phényl)éthyl] 1-aminocycloalk-1-ylcarboxamide substitués - 760 |
| WO2012119941A1 (fr) | 2011-03-04 | 2012-09-13 | Prozymex A/S | Composés de peptidylnitrile à titre d'inhibiteurs de peptidases |
| US8999975B2 (en) | 2011-09-19 | 2015-04-07 | Boehringer Ingelheim International Gmbh | Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C |
| JP6479476B2 (ja) | 2012-02-21 | 2019-03-06 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | SykチロシンキナーゼインヒビターおよびGCN2セリンキナーゼインヒビターとしての8−置換2−アミノー[1,2,4]トリアゾロ[1,5−A]ピラジン類 |
| CA2870527A1 (fr) | 2012-04-17 | 2013-10-24 | Astellas Pharma Inc. | Compose heterocyclique aromatique bicyclique azote |
| WO2014091443A1 (fr) | 2012-12-13 | 2014-06-19 | Glaxo Group Limited | Inhibiteurs de la cathepsine c pour traiter la mucoviscidose, la bronchectasie sans fibrose kystique, et la vascularite associée aux anca |
| EP2775304A1 (fr) | 2013-03-07 | 2014-09-10 | Universitätsspital Basel | Procédés de détection de troubles inflammatoires |
| JP6437929B2 (ja) | 2013-03-14 | 2018-12-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | カテプシンcの置換二環式1−カルボン酸(ベンジル−シアノ−メチル)−アミド阻害剤 |
| EA029052B1 (ru) | 2013-03-14 | 2018-02-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с |
| EP2970252B1 (fr) | 2013-03-14 | 2020-06-03 | Boehringer Ingelheim International GmbH | (benzyl-cyano-méthyl)-amides de l'acide 2-aza-bicyclo[2.2.2]octane-3-carboxylique substitués inhibiteurs de la cathepsine c |
| JP6441830B2 (ja) | 2013-03-14 | 2018-12-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | カテプシンcの置換2−アザ−ビシクロ[2.2.1]ヘプタン−3−カルボン酸(シアノ−メチル)−アミド阻害剤 |
| UY35400A (es) | 2013-03-15 | 2014-10-31 | Novartis Ag | Compuestos y composiciones para el tratamiento de enfermedades parasitarias |
| KR20150135328A (ko) | 2013-04-01 | 2015-12-02 | 풀매트릭스 인코퍼레이티드 | 티오트로피움 건조 분말 |
| WO2015027039A1 (fr) | 2013-08-22 | 2015-02-26 | Emory University | Dispositifs et procédés relatifs à une inflammation des voies aériennes |
| WO2015032942A1 (fr) | 2013-09-09 | 2015-03-12 | Prozymex A/S | 3,3'-(biphényl-4,4'-diyl)bis-2-aminopropanenitriles substitués en n en tant qu'inhibiteurs dppi |
| CN105612149A (zh) | 2013-09-09 | 2016-05-25 | 普罗技迈克斯公司 | 作为二肽基肽酶i抑制剂的肽基腈化合物 |
| GB201400034D0 (en) * | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
| NO2699580T3 (fr) | 2014-01-24 | 2018-02-24 | ||
| GB201402070D0 (en) * | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
| CN106456552A (zh) * | 2014-04-10 | 2017-02-22 | 诺华股份有限公司 | S1p调节剂的立即释放剂量方案 |
| MX384843B (es) | 2014-05-15 | 2025-03-14 | Insmed Inc | Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas. |
| CN107075557B (zh) | 2014-05-30 | 2021-07-06 | 香港大学 | 使用嗜中性粒细胞弹性蛋白酶和蛋白酶3作为诊断生物标志物的方法和组合物 |
| WO2016016242A1 (fr) | 2014-08-01 | 2016-02-04 | Boehringer Ingelheim International Gmbh | Oxétanes substitués et leur utilisation en tant qu'inhibiteurs de la cathépsine c |
| HUE047208T2 (hu) | 2014-09-12 | 2020-04-28 | Boehringer Ingelheim Int | A katepszin-C spirociklikus inhibitorai |
| MX370366B (es) | 2014-11-14 | 2019-12-11 | Boehringer Ingelheim Int | Amidas de morfolina y 1,4-oxazepano como agonistas del receptor de somatostatina subtipo 4 (sstr4). |
| DK3265452T3 (en) | 2015-03-05 | 2020-06-08 | Neuprozyme Therapeutics ApS | Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors |
| WO2018022978A1 (fr) * | 2016-07-29 | 2018-02-01 | Insmed Incorporated | Certains (2s)-n-[(1s)-1-cyano-2-phényléthyl]-1,4-oxazépane-2-carboxamides pour le traitement de la bronchectasie. |
| EP3749326A4 (fr) | 2018-02-07 | 2021-11-03 | Insmed Incorporated | Certains (2s)-n-[(1s)-1-cyano-2-phényléthyl]-1,4-oxazépane-2-carboxamides pour traiter les vascularites associées aux anca |
| PT3758708T (pt) | 2018-03-01 | 2025-02-13 | Astrazeneca Ab | Composições farmacêuticas compreendendo (2s)-{(1,s)-1-ciano-2-[4-(3-metil-2-oxo-2,3-di-hidro-1,3-benzoxazol-5-il)fenil]etil}-1,4-oxazepano-2-carboxamida |
| WO2020018551A1 (fr) | 2018-07-17 | 2020-01-23 | Insmed Incorporated | Certains (2s)-n-[(1s)-1-cyano-2-phényléthyl]-1,4-oxazépane-2-carboxamides pour le traitement d'une maladie intestinale inflammatoire |
| CA3106269A1 (fr) | 2018-07-17 | 2020-01-23 | Insmed Incorporated | Certains (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides pour le traitement d'une nephropathie lupique |
| EP4252844A3 (fr) | 2019-04-17 | 2023-12-06 | Azora Therapeutics, Inc. | Compositions topiques et méthodes de traitement de maladies cutanés |
| AU2020289560A1 (en) | 2019-06-05 | 2021-12-23 | Emory University | Peptidomimetics for the treatment of coronavirus and picornavirus infections |
| WO2022140516A1 (fr) | 2020-12-22 | 2022-06-30 | Insmed Incorporated | Certains ((25)-iv-[(ls')~ i-c yan0-2-phényléthyl·]-1,4-oxazépane-2-carboxamides pour le traitement de la maladie de behçet |
| CN112920124B (zh) | 2021-01-29 | 2024-03-01 | 安徽医科大学 | 一种嘧啶-2,4-二胺类化合物及其制备方法与应用 |
| WO2022232420A1 (fr) | 2021-04-29 | 2022-11-03 | Insmed Incorporated | Certains n-(1-cyano-2-phényléthyl)-1,4-oxazépane-2-carboxamides pour le traitement du cancer |
| US20240226112A1 (en) | 2021-04-29 | 2024-07-11 | Insmed Incorporated | Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis |
| CN118159525A (zh) | 2021-10-29 | 2024-06-07 | 英斯梅德股份有限公司 | 用于治疗慢性鼻窦炎的特定n-(1-氰基-2-苯乙基)-1,4-氧杂氮杂环庚烷-2-甲酰胺 |
| JP2025508359A (ja) | 2022-02-16 | 2025-03-26 | インスメッド インコーポレイテッド | 化膿性汗腺炎を治療するためのある特定のn-(1-シアノ-2-フェニルエチル)-1,4-オキサゼパン-2-カルボキサミド |
-
2019
- 2019-03-01 PT PT197162969T patent/PT3758708T/pt unknown
- 2019-03-01 EP EP19716296.9A patent/EP3758708B1/fr active Active
- 2019-03-01 PL PL19716296.9T patent/PL3758708T3/pl unknown
- 2019-03-01 AU AU2019228717A patent/AU2019228717C1/en active Active
- 2019-03-01 KR KR1020207028037A patent/KR102738945B1/ko active Active
- 2019-03-01 WO PCT/EP2019/055138 patent/WO2019166626A1/fr not_active Ceased
- 2019-03-01 CN CN201980028494.5A patent/CN112055593B/zh active Active
- 2019-03-01 ES ES19716296T patent/ES3011730T3/es active Active
- 2019-03-01 SM SM20250062T patent/SMT202500062T1/it unknown
- 2019-03-01 EP EP24212810.6A patent/EP4516353A3/fr active Pending
- 2019-03-01 FI FIEP19716296.9T patent/FI3758708T3/fi active
- 2019-03-01 HU HUE19716296A patent/HUE070049T2/hu unknown
- 2019-03-01 CA CA3091707A patent/CA3091707A1/fr active Pending
- 2019-03-01 CN CN202410348411.3A patent/CN118416077A/zh active Pending
- 2019-03-01 MD MDE20210035T patent/MD3758708T2/ro unknown
- 2019-03-01 KR KR1020247039864A patent/KR20250002710A/ko active Pending
- 2019-03-01 HR HRP20250115TT patent/HRP20250115T1/hr unknown
- 2019-03-01 LT LTEPPCT/EP2019/055138T patent/LT3758708T/lt unknown
- 2019-03-01 JP JP2020545547A patent/JP7336450B2/ja active Active
- 2019-03-01 RS RS20250139A patent/RS66494B1/sr unknown
- 2019-03-01 SI SI201930888T patent/SI3758708T1/sl unknown
- 2019-03-01 CN CN202410348413.2A patent/CN118416078A/zh active Pending
- 2019-03-01 US US16/975,292 patent/US12059424B2/en active Active
- 2019-03-01 DK DK19716296.9T patent/DK3758708T3/da active
- 2019-03-01 MA MA52424A patent/MA52424B1/fr unknown
-
2023
- 2023-08-21 JP JP2023133951A patent/JP2023156480A/ja active Pending
-
2024
- 2024-03-28 US US18/621,023 patent/US12201638B2/en active Active
- 2024-09-26 AU AU2024220121A patent/AU2024220121B2/en active Active
- 2024-12-09 US US18/974,778 patent/US20250108060A1/en active Pending
-
2026
- 2026-02-25 AU AU2026201419A patent/AU2026201419A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4516353A3 (fr) | Compositions pharmaceutiques comprenant du (2s)-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide | |
| MA55145B1 (fr) | Polythérapie incluant un inhibiteur de kras g12c et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers | |
| MA51204B1 (fr) | Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique | |
| GEAP202215540A (en) | Pcsk9 antagonist compounds | |
| TN2016000230A1 (en) | Orally disintegrating solid dosage unit containing an estetrol component. | |
| MA45782B1 (fr) | Modulateurs du récepteur de cxcr7 pipéridine | |
| ATE427740T1 (de) | Sedierende und nicht sedierende antihistamine enthaltende zusammensetzungen | |
| MA29791B1 (fr) | Composes therapeutiques. | |
| MA38358A1 (fr) | Formulations de composés organiques | |
| MA39164A1 (fr) | Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine | |
| CO6531485A2 (es) | Composiciones farmacéuticas sólidas que contienen un inhibidor de la integrasa | |
| MA42301B1 (fr) | Sel cristallin de fumarate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl)azétidin-1-yl]-méthanone | |
| CO2022005999A2 (es) | Inhibidores del factor d del complemento para administración oral | |
| MA39163A1 (fr) | Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine | |
| ECSP045493A (es) | Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a | |
| MA50201B1 (fr) | Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants | |
| MA32275B1 (fr) | Preparations orales et injectables de composes de tetracycline | |
| EA200501697A1 (ru) | Дозируемая форма, содержащая пантопразол в качестве активного ингредиента | |
| MA43913B1 (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
| TW200503785A (en) | Dosage form containing (S)-pantoprazole as active ingredient | |
| EA200600377A1 (ru) | Новая композиция | |
| AR035406A1 (es) | Procedimiento de preparacion de eletriptan | |
| EA201890929A1 (ru) | Низкие дозировки композиций дипиридамола для перорального приема и их использование | |
| MA29567B1 (fr) | (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl) amino]-1,3-thiazol-4(5h)-one | |
| MA40657A1 (fr) | Composition pharmaceutique stable comprenant du pemetrexed ou un sel pharmaceutiquement acceptable de celui-ci |